Patents by Inventor Nika Mindy Strokappe
Nika Mindy Strokappe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230374078Abstract: Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.Type: ApplicationFiled: June 28, 2023Publication date: November 23, 2023Inventors: Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Nika Mindy STROKAPPE, Daphné TRUAN
-
Patent number: 11820796Abstract: Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to an HIV envelope protein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, nucleic acid, and vectors.Type: GrantFiled: June 8, 2022Date of Patent: November 21, 2023Assignee: Janssen Vaccines & Prevention B.V.Inventors: Lucy Rutten, Daphné Truan, Nika Mindy Strokappe, Johannes Petrus Maria Langedijk
-
Patent number: 11732010Abstract: Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.Type: GrantFiled: February 22, 2021Date of Patent: August 22, 2023Assignee: Janssen Vaccines & Prevention B.V.Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Nika Mindy Strokappe, Daphné Truan
-
Publication number: 20220315627Abstract: Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to an HIV envelope protein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, nucleic acid, and vectors.Type: ApplicationFiled: June 8, 2022Publication date: October 6, 2022Inventors: Lucy Rutten, Daphné Truan, Nika Mindy Strokappe, Johannes Petrus Maria Langedijk
-
Patent number: 11365222Abstract: Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to an HIV envelope protein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, nucleic acid, and vectors.Type: GrantFiled: August 13, 2020Date of Patent: June 21, 2022Assignee: Janssen Vaccines & Prevention B.V.Inventors: Lucy Rutten, Daphné Truan, Nika Mindy Strokappe, Johannes P. M. Langedijk
-
Publication number: 20210188918Abstract: Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.Type: ApplicationFiled: February 22, 2021Publication date: June 24, 2021Inventors: Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Nika Mindy STROKAPPE, Daphné TRUAN
-
Patent number: 10968254Abstract: Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.Type: GrantFiled: July 19, 2018Date of Patent: April 6, 2021Assignee: Janssen Vaccines & Prevention B.V.Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Nika Mindy Strokappe, Daphné Truan
-
Publication number: 20200369731Abstract: Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to an HIV envelope protein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, nucleic acid, and vectors.Type: ApplicationFiled: August 13, 2020Publication date: November 26, 2020Inventors: Lucy Rutten, Daphné Truan, Nika Mindy Strokappe, Johannes P. M. Langedijk
-
Patent number: 10793607Abstract: Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to an HIV envelope protein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, nucleic acid, and vectors.Type: GrantFiled: September 14, 2017Date of Patent: October 6, 2020Assignee: Janssen Vaccines & Prevention B.V.Inventors: Lucy Rutten, Daphné Truan, Nika Mindy Strokappe, Johannes Petrus Maria Langedijk
-
Publication number: 20190023744Abstract: Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.Type: ApplicationFiled: July 19, 2018Publication date: January 24, 2019Inventors: Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Nika Mindy STROKAPPE, Daphné TRUAN
-
Publication number: 20180072777Abstract: Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to an HIV envelope protein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, nucleic acid, and vectors.Type: ApplicationFiled: September 14, 2017Publication date: March 15, 2018Inventors: Lucy RUTTEN, Daphné TRUAN, Nika Mindy STROKAPPE, Johannes Petrus Maria LANGEDIJK
-
Publication number: 20150158934Abstract: The invention relates to a novel class of broadly neutralizing anti-HIV antibodies, more specifically to broadly neutralizing heavy chain variable domain antibodies (VHH) and variants and modifications thereof. The invention further relates to methods for producing these antibodies and to the use of the antibodies for diagnostic and therapeutic and/or prophylactic treatment of individuals that are infected with HIV, or are at risk of becoming infected.Type: ApplicationFiled: September 10, 2012Publication date: June 11, 2015Applicants: UCL BUSINESS PLC, UNIVERSITEIT UTRECHT HOLDING B.V.Inventors: Laura Ellen Fleet McCoy, Lucy Rutten, Nika Mindy Strokappe, Cornelis Theodorus Verrips, Benjamin Lucian John Webb, Robert Anthony Weiss